THC: The Primary Psychoactive Cannabinoid

Delta-9-tetrahydrocannabinol (THC) is the primary psychoactive compound in *Cannabis sativa* and *Cannabis indica*, typically comprising 10-30% of dried flower depending on strain and cultivation [1]. As a terpenophenolic compound, THC belongs to the cannabinoid class of molecules that interact with the human endocannabinoid system. Unlike CBD, THC produces intoxicating effects through direct activation of cannabinoid receptors.

While cannabis remains THC's primary natural source, trace amounts occur in other plants including *Rhododendron* species and certain liverworts, though at concentrations far too low for psychoactive effects [2]. The compound exists in several isomers, but delta-9 THC represents the most abundant and pharmacologically active form found in cannabis.

THC's significance extends beyond recreational use. Its unique receptor binding profile and psychoactive properties make it distinct among cannabinoids, driving both therapeutic applications and regulatory complexity across jurisdictions. Understanding THC is essential for anyone working with cannabis-derived products, as it largely determines legal classification and user experience.

THC functions primarily as a partial agonist of CB1 cannabinoid receptors, which are densely concentrated in brain regions controlling cognition, memory, motor coordination, and reward processing [3]. This receptor activation triggers a cascade of neurochemical changes, including increased dopamine release in the nucleus accumbens and altered GABA and glutamate signaling, producing THC's characteristic psychoactive effects.

The compound's effects follow a biphasic pattern: low doses often produce relaxation and mild euphoria, while higher doses can trigger anxiety, paranoia, or cognitive impairment. Peak plasma concentrations occur 6-10 minutes after inhalation or 1-3 hours after oral consumption, with psychoactive effects lasting 1-4 hours (inhaled) or 4-8 hours (oral) [4].

THC also activates CB2 receptors in immune tissue, contributing to anti-inflammatory and immunomodulatory effects. The compound interacts synergistically with other cannabis constituents—particularly terpenes like myrcene and limonene—in what researchers term the "entourage effect," though the clinical significance of these interactions remains under investigation [5].

Clinical evidence supports THC's efficacy for several therapeutic applications. Note: Dronabinol is an FDA-approved prescription drug, distinct from botanical cannabis products. This information describes pharmaceutical research, not dietary supplements [6]. Meta-analyses demonstrate moderate evidence for THC's effectiveness in chronic pain management, particularly neuropathic pain, with effect sizes comparable to traditional analgesics [7].

Emerging research suggests THC may benefit sleep disorders, with studies showing reduced sleep latency and increased slow-wave sleep at low doses (2.5-15mg) [8]. However, chronic use can disrupt REM sleep and lead to tolerance. For epilepsy, while CBD receives more attention, some evidence indicates THC may enhance seizure control when combined with other cannabinoids, though research remains limited [9].

Significant gaps exist in our understanding of optimal dosing, long-term effects, and individual response variability. Most clinical trials use synthetic THC rather than whole-plant cannabis, limiting applicability to consumer products. Additionally, research restrictions have historically limited large-scale, long-term studies needed to fully characterize THC's therapeutic potential and risks.

When evaluating cannabis products, THC content is the primary determinant of psychoactive intensity and legal status. Certificate of Analysis (COA) reports should specify both THCA (the non-psychoactive precursor) and activated THC levels, as heat converts THCA to psychoactive THC during consumption. We look for products testing below 0.3% delta-9 THC to ensure federal compliance in hemp-derived products.

Dosing varies dramatically by consumption method and individual tolerance. For newcomers, we recommend starting with 1-2.5mg THC (edibles) or single small inhalations (flower/vapes), waiting at least 2 hours before additional dosing. Edible THC undergoes first-pass liver metabolism, converting to 11-hydroxy-THC—a more potent metabolite producing different effects than inhaled THC [10].

The THC:CBD ratio significantly influences user experience. High-THC products (>20mg THC with minimal CBD) tend toward intense psychoactive effects, while balanced ratios (1:1 to 1:4 THC:CBD) often provide therapeutic benefits with reduced anxiety or paranoia. For therapeutic applications, consistent daily micro-dosing (1-5mg) may prove more effective than occasional high doses, though individual response varies considerably.